(UroToday.com) Atezolizumab (anti–PD-L1) monotherapy is approved for cisplatin-ineligible patients who have locally advanced or metastatic urothelial carcinoma with PD-L1–expressing immune cells on ≥ 5% of the tumor area (IC2/3 per VENTANA SP142 IHC assay).1 The IMvigor130 primary analysis demonstrated a significant progression free survival benefit with atezolizumab plus platinum/gemcitabine (Arm A) versus placebo platinum/gemcitabine (Arm C) as first-line treatment formetastatic urothelial carcinoma.2. At that time, interim overall survival data for Arm A versus Arm C were encouraging but immature. Overall survival with atezolizumab monotherapy (Arm B) could not be formally tested, but favorable efficacy was seen in IC2/3 patients. At the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), Dr. Matthew Galsky and colleagues presented results of their exploratory analysis of IMvigor130 assessing outcomes by PD-L1 status in cisplatin-ineligible patients.